Cartesian Therapeutics Inc.
RNAC | NASDAQ
$8.13
+$0.19 (+2.39%)
Sep 22, 2026, 2:34 PM ET · Market open
Market Data
Market Cap $233.29M
Enterprise Value $96.69M
Beta 0.62
Average Volume 230.3K
Shares Outstanding (Diluted) 29.86M
Shares Change YoY 12.91%
Institutional Ownership 26.63%
Exchange NASDAQ
ISIN US8162123025
Price Performance
Price Change 1M -22.0%
Price Change 3M -22.0%
Price Change 6M 27.0%
Price Change YTD 17.5%
Price Change 1Y -20.9%
Price Change 3Y -75.0%
Price Change 5Y -93.9%
1M CAGR (ann.) -10.3%
1Y CAGR (ann.) -23.0%
5Y CAGR (ann.) -42.8%
All-Time CAGR -32.1%
Valuation
PE Ratio -1.36
Forward PE N/A
PEG Ratio 0.01
Forward PEG -0.03
PS Ratio 157.95
Forward PS 699.90
PB Ratio -1.86
P/FCF Ratio -2.98
P/Adj. FCF Ratio -2.67
P/OCF Ratio -3.08
EV/Sales 65.46
EV/EBIT -0.60
EV/EBITDA -0.61
EV/FCF -1.24
Earnings Yield -73.5%
FCF Yield -33.5%
Adj. FCF Yield -37.5%
Financial Health
Net Cash $136.6M
Total Debt $11M
Cash & Short-Term Investments $147.61M
Total Assets $318.63M
Current Ratio 7.48
Quick Ratio 7.48
Debt / Equity Ratio -0.51
Debt / EBITDA -0.07
Debt / FCF -0.14
OCF / Debt -6.91
Interest Coverage -115.80
Altman Z-Score -4.55
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin -766.4%
Operating Profit Margin -6679.7%
EBITDA Margin -10670.5%
Net Profit Margin -10422.5%
FCF Margin -5291.5%
Adj. FCF Margin -5917.1%
SBC / Revenue 625.6%
SBC Impact (per share) -11.8%
Returns
Return on Assets -48.3%
Return on Equity 141.4%
Return on Invested Capital -30.8%
Return on Capital Employed -33.1%
Return on Tangible Assets -87.2%
Historical Growth (CAGR)
Revenue CAGR 3Y -68.8%
Revenue CAGR 5Y -50.0%
Revenue CAGR 10Y -15.4%
EPS CAGR 3Y 117.8%
EPS CAGR 5Y -16.3%
EPS CAGR 10Y 26.3%
FCF CAGR 3Y -10.4%
FCF CAGR 5Y -7.0%
FCF CAGR 10Y -6.0%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 10
EPS Growth Next 3Y 13.2%
Revenue Growth Next 3Y 289.3%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$1.02
EPS Growth Est (next Q) -26.1%
Revenue Est (next Q) $180K
Revenue Growth Est (next Q) -60.2%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $25
Price Target Upside 214.9%
Cash Flow
Operating Cash Flow $-76.07M
Free Cash Flow $-78.16M
Adj. Free Cash Flow $-87.4M
FCF Per Share -$2.65
OCF Per Share -$2.58
OCF/S Ratio -5150.5%
Income Statement
Revenue $1.48M
Gross Profit $-11.32M
Operating Income $-98.66M
EBITDA $-157.6M
Net Income $-153.94M
EPS (Diluted) -$5.84
Revenue / Employee $19.69K
Profit / Employee $-2.05M
Employees 75
Add to Watchlist
Select watchlists to add or remove RNAC